<DOC>
	<DOCNO>NCT02083406</DOCNO>
	<brief_summary>A single dose study investigate different formulation OZ439 co-administered PQP tablest process body take without food</brief_summary>
	<brief_title>Bioavailability Study Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate ( PQP )</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Healthy male , healthy female nonchildbearing potential ie surgically sterilise postmenopausal ( amenorrhoea least 1 year confirm follicle stimulate hormone result ≥25 IU/mL 2 . Age 18 55 year age 3 . Body mass index 18.0 30.0 kg/m2 inclusive . Total body weight &gt; 50 kg screen 4 . Willing able communicate participate whole study 5 . Must provide write informed consent 6 . Must agree use adequate method contraception 7 . Must liver function test haemoglobin within laboratory reference range screen Day 1 8 . Must heart trace measurement within define healthy limit screen , Day 1 predose 1 . Male subject currently pregnant partner 2 . Evidence history clinically significant oncological , pulmonary , chronic respiratory , hepatic , cardiovascular , haematological , metabolic , neurological , immunological , nephrological , endocrine psychiatric disease , current infection 3 . Clinically relevant abnormality heart trace include degree heart block , include asymptomatic bundle branch block 4 . Family history sudden death congenital prolongation QTc interval know congenital prolongation QTc interval clinical condition know prolong QTc interval 5 . History symptomatic cardiac arrhythmia clinically relevant bradycardia 6 . Electrolyte disturbance , particularly hypokalemia , hypocalcaemia hypomagnesaemia . 7 . Any condition could possibly affect drug absorption , gastrectomy diarrhoea 8 . History postantibiotic colitis 9 . History drug alcohol abuse past 2 year prior screen 10 . Subjects breath carbon monoxide read great 10 ppm screening exclude . Subjects tobacco user ( include smoker user snuff , chew tobacco nicotine nicotinecontaining product ) must stop use within 90 day screen . 11 . Receipt investigational drug participation another clinical research study within 90 day prior drug administration . 12 . Subjects study site employee , immediate family member study site sponsor employee . 13 . Subjects previously enrol study 14 . Use ANY prescription nonprescription medication , vitamin , herbal supplement dietary supplement , include protein supplement , within 14 day prior first dose study drug throughout study , unless prior approval grant investigator sponsor . An exception make intermittent use paracetamol hormone replacement therapy . Paracetamol dose , , 2 g per day 3 consecutive day 6 non consecutive day , allow 24 hour dose study drug . Longer exclusion period apply : 1. amiodarone hydroxychloroquine ( 210 day ) 2. monoclonal antibodies/ immunoglobulins/ therapeutic protein experimental drug halflife know investigator ( 120 day ) 3. experimental drug halflife know investigator ( 5 half life plus 14 day ) 4. chloroquine , piperaquine phosphate flunarizine ( 100 day ) 5. fluoxetine ( 75 day ) 6. benzodiazepine ( midazolam , lorazepam triazolam , exclusion period 14 day ) , chlorpromazine , mephenytoin , nortryptyline , phenobarbital , primidone , phenprocoumone cytochrome P450 3A4 inducer already mention , include restrict , rifampin , carbamazepine , oxcarbazepine , phenytoin St John 's Wort ( 35 day ) 15 . Positive hepatitis B surface antigen , hepatitis C virus antibody human immunodeficiency virus result 16 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 17 . Positive urine drug screen result screen admission clinical unit 18 . History intolerance hypersensitivity piperaquine 4aminoquinolone , ascertain presumptive hypersensitivity active principle and/or formulation ingredient ; history anaphylaxis drug allergic reaction general , investigator considers may affect outcome study 19 . Serious adverse reaction serious hypersensitivity drug formulation excipients 20 . Presence history allergy require treatment ; hayfever allow unless active 21 . Donation loss &gt; 400 mL blood within 90 day prior drug administration 22 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 23 . Subjects suitable vein multiple blood sample assess investigator screen 24 . Failure satisfy investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Bio-availability</keyword>
</DOC>